lpca Laboratories Collaborates with Omexa Formulary for Biosimilar Development
lpca Laboratories Ltd’s stock experienced a 0.78% increase following the finalization of a tech transfer agreement with Omexa Formulary Pvt Ltd. The agreement focuses on biosimilar development for the global market.
Empowering Innovation
In this strategic partnership, lpca will provide Omexa with a non-exclusive right to conduct research, development, manufacturing, and marketing of an anti-cancer biosimilar on a global scale. This collaboration marks a significant step towards advancing biosimilar development from initial stages to clinical trials and eventual commercialization.
Visionary Leadership
Pranay Godha, the Managing Director and CEO of lpca Laboratories, expressed enthusiasm about the collaboration. He highlighted the potential for Omexa to establish a robust foundation for the development of anti-cancer and anti-inflammatory monoclonal antibody products. Godha emphasized the importance of delivering affordable and high-quality biologic medications to address the unmet needs of patients with chronic illnesses worldwide.
Market Impact
Following the announcement, lpca’s shares rose by 0.78% to ₹1,210.50 at 2:08 pm on the Bombay Stock Exchange (BSE). The partnership between lpca Laboratories and Omexa Formulary signifies a commitment to advancing healthcare solutions and meeting global standards in biosimilar development.
Stay tuned for more updates on the evolving landscape of biotechnology and pharmaceutical collaborations.
